Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Slides:

Advertisements

Similar presentations

Cancer immunotherapy: an update

Advertisements

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Immune Receptors and Signal Transduction

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll Cancer Cell

Concepts of cancer immunotherapy

Immune Tolerance Kyeong Cheon Jung Department of Pathology

Prot eins Immune Checkpoint. CONTENTS Page 3 Immune System Page 7 Cancer and Immune Response Page 9 Immuno-Oncology Page 12 Immune Checkpoint Proteins.

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 Key elements of cancer-related inflammation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Radiation-induced effects on tumour cells

Figure 2 Immune-escape mechanisms of CTCs in the peripheral blood

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Signalling pathways and physiological domains that are

Figure 3 Altered adaptive immune functions after sepsis

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 1 Chimeric antigen receptor (CAR) structures

Cancer Immunotherapy by Dendritic Cells

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Figure 7 Clinical options for HCC therapy

Oncology Meets Immunology: The Cancer-Immunity Cycle

Figure 1 Immune mechanisms in liver homeostasis

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Classification of immunotherapies

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 CAR-T-cell design

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 TNFSF activities enhancing immune cell activation

Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 6 Combination therapy for HCC

Figure 4 Approaches to targeting inhibitory immune receptors

Nat. Rev. Urol. doi: /nrurol

Figure 4 Macrophage-targeting antitumour treatment approaches

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Miki Ando, Hiromitsu Nakauchi Experimental Hematology

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Leonardo V. Riella, Mohamed H. Sayegh Kidney International Supplements

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The role of CTLA4 and PD1 in T cell activation

Targets for immunotherapy of liver cancer

Figure 2 Approaches to improve CAR-T-cell therapy

Checkpoint blockade therapy resistance in Hodgkin's lymphoma

Figure 2 Site of action of checkpoint inhibitors and agonists being

Mechanisms of immune escape in the tumor microenvironment.

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit Kristen E. Pauken,

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 1 Mechanisms of action of immunotherapy modalities

Nat. Rev. Urol. doi: /nrurol

Shifting the Evolving CAR T Cell Platform into Higher Gear

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Genetically modified TCRs for cancer immunotherapy.

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Figure 4 Molecular signalling and immunological

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Presentation transcript:

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression. a | Overview of the immune inhibitory molecules that compromise endogenous T-cell antitumour activity. T cells are susceptible to immune inhibitory factors associated within the microenvironment that prevent their full antitumour activity. Such factors include cell surface proteins (such as programmed cell death 1 ligands 1 and 2 (PD-L1 and PD-L2)) and cytokines (such as TGF-β and IL-10). Regulatory T cells (TREG) are representative of inhibitory cellular components of the tumour microenvironment (TME), which also include myeloid-derived suppressor cells, tumour-associated macrophages and other cell types non-depicted. b | Similarly to endogenous T cells, CAR T cells are susceptible to immune inhibitory factors present in the TME. c | Immunomodulatory monoclonal antibodies can be used to overcome local immunosuppression by either activating stimulatory receptors (such as TNFRSF9 (4-1BB) or OX40), or blocking suppressive receptors (for example, programmed cell-death 1 (PD-1) or cytotoxic T-lymphocyte antigen 4 (CTLA-4)). d | Armoured CAR T cells are engineered to express proteins that overcome immunosuppression associated with the TME (such as CD40L, IL-12 or TNFSF9 [4-1BBL]). Ag, antigen; APC, antigen-presenting cell; CD40L, CD40 ligand; Cy, cyclophosphamide; DC, dendritic cell; Flu, fludarabine; GITR, glucocorticoid-induced TNFR family related protein; GITRL, GITR ligand; HMGB1, high mobility group 1 protein; LAG-3, lymphocyte activation gene-3; PSer, phosphatidyl serine; scFv, single-chain variable fragment; TCR, T-cell receptor; TIGIT, T-cell immunoreceptor with immunoglobulin and ITIM domains; TIL, tumour -nfiltrating lymphocyte; TIM-3, T cell immunoglobulin and mucin domain 3. Khalil, D. N. et al. (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.25